PUBLISHER: IMARC | PRODUCT CODE: 1541547
PUBLISHER: IMARC | PRODUCT CODE: 1541547
The global actinic keratosis treatment market size reached US$ 6.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.
Actinic keratosis, also known as solar keratosis, refers to a skin condition that develops on the sun-exposed areas of the body. It causes rough, scaly patches to appear on the hands, arms, lips, scalp, and other body parts that can further develop into a skin cancer called squamous cell carcinoma. Some of the commonly used treatments to remove actinic keratosis include cryotherapy, curettage, laser therapy, and photodynamic therapy. At present, the considerably expanding healthcare infrastructure and increasing need for preventive strategies for cancer are positively influencing the demand for actinic keratosis treatment worldwide.
The increasing prevalence of actinic keratosis due to ozone layer depletion and excessive sun exposure represents one of the key factors fueling the growth of the market. Additionally, the rising incidences of cancer, coupled with the escalating demand for minimally invasive (MI) procedures, is strengthening the market growth. Furthermore, leading manufacturers are introducing medications for the treatment of actinic keratosis in the form of cream and gel, which is impelling the market growth. Apart from this, numerous public and private groups are focusing on conducting campaigns to generate awareness about available treatments for actinic keratosis across the globe. This, along with significant investments in the research and development (R&D) activities to develop novel therapies with improved efficacy, convenient dosage, and reduced costs, is creating a favorable market outlook. The market is also driven by the introduction of topical treatment that reduces the risk of scarring. This treatment is also used for treating a wide area of visible and invisible lesions on the skin. Besides this, favorable reimbursement policies are anticipated to fuel the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global actinic keratosis treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug type, and distribution channel.
Prescription
OTC
Fluorouracil
Imiquimod
Diclofenac
Others
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Almirall SA, Bausch Health Companies Inc., Biofrontera Inc., BioLineRx Ltd., Cipher Pharmaceuticals Inc, Galderma SA, Hill Dermaceuticals Inc., LEO Pharma A/S and Sun Pharmaceutical Industries Ltd.